| "The voice for cancer physicians and their patients in Massachusetts." |
- Home
- Advocacy
AdvocacyMay 24, 2019: MSCO Presents Comments Before the Health Policy Commission regarding the impact of coupons, discounts, and other product vouchers for prescription drugs. The following letter was submitted to the Public Listening Session of Health Policy Commission:
May 19, 2017: MSCO and ASCO Comment on the Proposed Regulation 243 CMR 2.07 (14), entitled "Providing Cancer Patients with Treatment Information." The Massachusetts Society of Clinical Oncologists (MSCO) and the American Society of Clinical Oncologists (ASCO) provide testimony and comments to the Massachusetts Board of the Registration in Medicine regarding proposed regulation 243 CMR 2.07 (14), entitled "Providing Cancer Patients with Treatment Information." The following letter had been delivered at a public hearing by Dr. Omar Eton (Boston Medical Center) and submitted to the Board of Registration in Medicine:
MSCO and ASCO Comment on H. 2458 - An Act Relative to the Safe Handling of Hazardous Drugs The Massachusetts Society of Clinical Oncologists (MSCO) and the American Society of Clinical Oncologists (ASCO) provide comments on the Massachusetts Health Bill 2458. The following letter has been submitted to the Honorable Chairs and Members of the Joint Committee on Public Health:
|
